Anshul Maheshwari Sells 18,542 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 18,542 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $373,621.30. Following the completion of the sale, the chief financial officer directly owned 185,231 shares of the company’s stock, valued at approximately $3,732,404.65. This represents a 9.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The stock was sold at an average price of $20.00, for a total value of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total transaction of $24,012.00.
• On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The stock was sold at an average price of $17.43, for a total value of $60,307.80.
• On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33.
• On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The shares were sold at an average price of $14.20, for a total transaction of $47,016.20.

SiBone Stock Up 0.6%

SIBN traded up $0.13 on Friday, hitting $20.38. 711,205 shares of the company were exchanged, compared to its average volume of 452,878. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The company has a market cap of $884.31 million, a price-to-earnings ratio of -39.96 and a beta of 0.76. The firm has a 50-day moving average price of $17.31 and a two-hundred day moving average price of $16.86. SiBone has a twelve month low of $12.49 and a twelve month high of $20.80.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The company had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. On average, equities analysts predict that SiBone will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On SiBone

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock valued at $41,777,000 after purchasing an additional 521,683 shares during the last quarter. First Light Asset Management LLC raised its position in shares of SiBone by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company’s stock valued at $22,622,000 after purchasing an additional 475,426 shares in the last quarter. Wellington Management Group LLP raised its position in shares of SiBone by 74.7% in the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock valued at $12,560,000 after purchasing an additional 364,897 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of SiBone during the 2nd quarter valued at approximately $6,664,000. Finally, Impax Asset Management Group plc grew its position in shares of SiBone by 48.2% during the third quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after buying an additional 333,249 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Morgan Stanley lifted their price objective on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial raised their target price on SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC boosted their price objective on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price objective on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of SiBone in a research report on Monday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.